General Information of the Protein
Protein ID
PT01637
Protein Name
Phospholipase A2
Secondarily
Protein Name
Group IB phospholipase A2
Phosphatidylcholine 2-acylhydrolase 1B
Gene Name
PLA2G1B
Secondarily
Gene Name
PLA2
PLA2A
PPLA2
Sequence
MKLLVLAVLLTVAAADSGISPRAVWQFRKMIKCVIPGSDPFLEYNNYGCYCGLGGSGTPVDELDKCCQTHDNCYDQAKKLDSCKFLLDNPYTHTYSYSCSGSAITCSSKNKECEAFICNCDRNAAICFSKAPYNKAHKNLDTKKYCQS
    Show/Hide
Organism
Homo sapiens, Human
Protein Classification
Enzyme
>
Hydrolase
Function
Secretory calcium-dependent phospholipase A2 that primarily targets dietary phospholipids in the intestinal tract (PubMed:1420353, PubMed:10681567, PubMed:17603006). Hydrolyzes the ester bond of the fatty acyl group attached at sn-2 position of phospholipids (phospholipase A2 activity) with preference for phosphatidylethanolamines and phosphatidylglycerols over phosphatidylcholines (PubMed:1420353, PubMed:10681567, PubMed:17603006). May play a role in the biosynthesis of N-acyl ethanolamines that regulate energy metabolism and inflammation in the intestinal tract. Hydrolyzes N-acyl phosphatidylethanolamines to N-acyl lysophosphatidylethanolamines, which are further cleaved by a lysophospholipase D to release N-acyl ethanolamines (By similarity). May act in an autocrine and paracrine manner (PubMed:7721806, PubMed:25335547). Upon binding to the PLA2R1 receptor can regulate podocyte survival and glomerular homeostasis (PubMed:25335547). Has anti-helminth activity in a process regulated by gut microbiota. Upon helminth infection of intestinal epithelia, directly affects phosphatidylethanolamine contents in the membrane of helminth larvae, likely controlling an array of phospholipid-mediated cellular processes such as membrane fusion and cell division while providing for better immune recognition, ultimately reducing larvae integrity and infectivity (By similarity).
    Show/Hide
Uniprot ID
Primary ID:
P04054

Secondarily ID:
B2R4H5
Q3KPI1
    Show/Hide
Ensembl ID
ENSG00000170890
HGNC ID
HGNC:9030
Subcellular Location
Secreted
Clinical Information about the Protein
Target 1 ( Phospholipase A2 (PLA2G1B) )
Target Type Successful Target
Disease 8 Target-related Diseases  8
1 Synthesis disorder [ICD-11: 5C52-5C59]
2 Leishmaniasis [ICD-11: 1F54]
3 Arthritis [ICD-11: FA20]
4 Metabolic syndrome x [ICD-11: 5C50-5D2Z]
5 Snakebite [ICD-11: N.A.]
6 Cardiovascular disease [ICD-11: BA00-BE2Z]
7 Arteriosclerosis [ICD-11: BD40]
8 Rheumatoid arthritis [ICD-11: FA20]
Approved Drug(s) 2 Approved Drugs  2
1 Cholic Acid Approved
Synthesis disorder
2 Miltefosine Approved
Leishmaniasis
Clinical Trial Drug(s) 4 Clinical Trial Drugs  4
1 MANOALIDE Phase 2
Arthritis
2 URSOLIC ACID Phase 2
Metabolic syndrome x
3 Varespladib Phase 2
Snakebite
4 Rilapladib Phase 1
Cardiovascular disease
Discontinued Drug(s) 3 Discontinued Drugs  3
1 Darapladib Discontinued in Phase 3
Arteriosclerosis
2 SB-435495 Discontinued in Phase 1
Arteriosclerosis
3 YM-26734 Terminated
Rheumatoid arthritis